medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2015-7-32-43medsovet-208Research ArticleЭндокринологияEndocrinologyДиабетическая нефропатия. Зависит ли ренопротекция от выбора сахароснижающей терапии?Diabetic nephropathy. Is renoprotection determined by the choice of hypoglycemic therapy?БабенкоА. Ю.BabenkoA. Y.noemail@neicon.ruБайрашеваВ. К.BayrashevaV. K.noemail@neicon.ruСеверо-Западный федеральный медицинский исследовательский центр им. В.А. Алмазова Минздрава России, Институт эндокринологии, Санкт-ПетербургРоссияFederal North-West Medical Research Centre, Ministry of Health of the Russian Federation, Institute of Endocrinology, St. PetersburgRussian Federation201530122015073243Copyright © Бабенко А.Ю., Байрашева В.К., 20152015Бабенко А.Ю., Байрашева В.К.Babenko A.Y., Bayrasheva V.K.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/208

Начало XXI в. в диабетологии характеризуется серьезным прорывом в разработке новых фармакологических агентов и изменением подходов к лечению сахарного диабета 2-го типа. Изменение концепции подхода к лечению с глюкоцентрической на многофакторную и создание новых групп противо-диабетических препаратов с множественными негликемическими эффектами существенно усложнило для практикующих врачей выбор терапии для каждого конкретного больного, но в то же время позволило сделать его максимально оптимальным. Это, несомненно, требует расширения знаний специалистов о негликемических эффектах противодиабетических лекарственных средств. Настоящий обзор посвящен одному из таких эффектов - ренопротективным влияниям различных групп сахароснижаю-щих препаратов, с акцентом на новые группы, вошедшие в российские алгоритмы за последнее десятилетие (агонисты рецепторов ГПП-1, ингибиторы ДПП-4, ингибиторы натрий-глюкозного ко-транспортера 2-го типа). Он может быть полезен как исследователям, так и практикующим врачам, старающимся на современном уровне выбирать оптимальную терапию для своих пациентов.

The beginning of XXI century in diabetology is characterized by a major breakthrough in the development of new pharmacological agents and new approaches to the treatment of type 2 diabetes. The move from glucose-centric to multifactorial concept of treatment and creation of the new groups of antidiabetic drugs with multiple properties not effecting glycemia have considerably complicated though greatly improved practitioner's choice of therapy for an individual patient. This undoubtedly calls for a greater knowledge of specialists about non-glycemic effects of antidiabetic drugs. This review is devoted to renoprotective effect demonstrated by various groups of antidiabetic drugs, focusing on new groups of drugs included in the Russian algorithms over the past decade (GLP-1 receptor agonists, DPP-4 inhibitors, sodium-glucose cotransporter 2 inhibitors). It can be useful to both researchers and clinicians who are striving to offer the therapy of choice to their patients today.

диабетическая нефропатияренопротекцияпротиводиабетические препаратыартериальное давлениеметформинпрепараты сульфонилмочевинытиазолидиндионыингибиторыдипептидилпептидазы-4агонисты рецепторов глюкагоноподобного пептида-1ReferencesTriggLe CR, Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis. 2014, 5(6): 245-268TriggLe CR, Ding H. Cardiovascular impact of drugs used in the treatment of diabetes. Ther Adv Chronic Dis. 2014, 5(6): 245-268PLantinga LC, Crews DC, Coresh J, et aL. Prevalence of chronic kidney disease in US aduLts with undiagnosed diabetes or prediabe-tes. Clin J Am Soc Nephrol. 2010, 5(4):673-682.PLantinga LC, Crews DC, Coresh J, et aL. Prevalence of chronic kidney disease in US aduLts with undiagnosed diabetes or prediabe-tes. Clin J Am Soc Nephrol. 2010, 5(4):673-682.Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я. и соавт. Федеральные клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных сахарным диабетом. М., 2014. 39 c.Шестакова М.В., Шамхалова М.Ш., Ярек-Мартынова И.Я. и соавт. Федеральные клинические рекомендации по диагностике, скринингу, профилактике и лечению хронической болезни почек у больных сахарным диабетом. М., 2014. 39 c.KDOOI clinical practice guideline for diabetes and CKD: 2012 update. Am J of Kidn Dis, 2012, 60(5): 850-886.KDOOI clinical practice guideline for diabetes and CKD: 2012 update. Am J of Kidn Dis, 2012, 60(5): 850-886.Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes meLLitus. Mayo Clin Proc, 2011, 86(5): 444-456.Bakris GL. Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes meLLitus. Mayo Clin Proc, 2011, 86(5): 444-456.Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoaLbuminuric type 1 diabetic patients: an indicator of more advanced glomerular Lesions. Diabetes, 2003, 52: 1036-1040.Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoaLbuminuric type 1 diabetic patients: an indicator of more advanced glomerular Lesions. Diabetes, 2003, 52: 1036-1040.Kramer CK, Leitao CB, Pinto LC, et aL. CLinicaL and Laboratory profiLe of patients with type 2 diabetes with Low gLomeruLar fiLtration rate and normoaLbuminuria. 2007, 30(8):1998-2000.Kramer CK, Leitao CB, Pinto LC, et aL. CLinicaL and Laboratory profiLe of patients with type 2 diabetes with Low gLomeruLar fiLtration rate and normoaLbuminuria. 2007, 30(8):1998-2000.Kramer HJ, Nguyen OD, Curhan G, Hsu CY. RenaL insufficiency in the absence of aLbuminuria and retinopathy among aduLts with type 2 diabetes meLLitus. JAMA, 2003, 289: 3273-3277.Kramer HJ, Nguyen OD, Curhan G, Hsu CY. RenaL insufficiency in the absence of aLbuminuria and retinopathy among aduLts with type 2 diabetes meLLitus. JAMA, 2003, 289: 3273-3277.HoLman RR, PauL SK, BetheL MA, et aL. 10-year foLLow-up of intensive gLucose controL in type 2 diabetes. N Engl J Med, 2008, 359(15): 15771589.HoLman RR, PauL SK, BetheL MA, et aL. 10-year foLLow-up of intensive gLucose controL in type 2 diabetes. N Engl J Med, 2008, 359(15): 15771589.Zhang OL, Rothenbacher D. PrevaLence of chronic kidney disease in popuLation-based studies: systematic review, 2008, 11(8):117. doi: 10.1186/1471-2458-8-117.Zhang OL, Rothenbacher D. PrevaLence of chronic kidney disease in popuLation-based studies: systematic review, 2008, 11(8):117. doi: 10.1186/1471-2458-8-117.BadaL SS, Danesh FR. New insights into moLecuLar mechanisms of diabetic kidney disease. Am J Kidney Dis, 2014, 63: S63-83.BadaL SS, Danesh FR. New insights into moLecuLar mechanisms of diabetic kidney disease. Am J Kidney Dis, 2014, 63: S63-83.SatcheLL SC, Tooke JE. What is the mechanism of microaLbuminuria in diabetes: a roLe for the gLomeruLar endotheLium? Diabetologia, 2008, 51(5): 714-725.SatcheLL SC, Tooke JE. What is the mechanism of microaLbuminuria in diabetes: a roLe for the gLomeruLar endotheLium? Diabetologia, 2008, 51(5): 714-725.Iwasaki H, Okamoto R, Kato S. High gLucose induces pLasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kB activation in bovine aortic endotheLiaL ceLLs. AtheroscLerosis, 2008, 196 (1): 22-28.Iwasaki H, Okamoto R, Kato S. High gLucose induces pLasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kB activation in bovine aortic endotheLiaL ceLLs. AtheroscLerosis, 2008, 196 (1): 22-28.Bottinger EP , Bitzer M. TGF-p signaLing in renaL disease. CLin J Am Soc NephroL, 2002, 13(10): 2600-2610.Bottinger EP , Bitzer M. TGF-p signaLing in renaL disease. CLin J Am Soc NephroL, 2002, 13(10): 2600-2610.G^de P, VedeL P, Larsen N, et aL. MuLtifactoriaL intervention and cardiovascuLar disease in patients with type 2 diabetes. N EngL J Med, 2003, 348 (5): 383-393.G^de P, VedeL P, Larsen N, et aL. MuLtifactoriaL intervention and cardiovascuLar disease in patients with type 2 diabetes. N EngL J Med, 2003, 348 (5): 383-393.Lacquaniti A, BoLignano D, Donato V, et aL. ALterations of Lipid metaboLism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney BLood Press Res, 2010, 33(2):100-110.Lacquaniti A, BoLignano D, Donato V, et aL. ALterations of Lipid metaboLism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney BLood Press Res, 2010, 33(2):100-110.Ozsoy RC, van der Steeg WA, KasteLein JJ, et aL. DysLipidaemia as predictor of progressive renaL faiLure and the impact of treatment with atorv-astatin. NephroL DiaL TranspLant, 2007, 22(6):1578-1586.Ozsoy RC, van der Steeg WA, KasteLein JJ, et aL. DysLipidaemia as predictor of progressive renaL faiLure and the impact of treatment with atorv-astatin. NephroL DiaL TranspLant, 2007, 22(6):1578-1586.Gouva C, NikoLopouLos P, loannidis JP, Siamopou-Los KC. Treating anemia earLy in renaL faiLure patients sLows the decLine of renaL function: a randomized controLLed triaL. Kidney Int, 2004, 66(2): 753-760Gouva C, NikoLopouLos P, loannidis JP, Siamopou-Los KC. Treating anemia earLy in renaL faiLure patients sLows the decLine of renaL function: a randomized controLLed triaL. Kidney Int, 2004, 66(2): 753-760CignareLLi M, Lamacchia O, Di PaoLo S, GesuaLdo L. Cigarette smoking and kidney dysfunction in diabetes meLLitus. J NephroL, 2008, 21(2)180-189.CignareLLi M, Lamacchia O, Di PaoLo S, GesuaLdo L. Cigarette smoking and kidney dysfunction in diabetes meLLitus. J NephroL, 2008, 21(2)180-189.Ting SM, Nair H, Ching I, et aL. Overweight, obesity and chronic kidney disease. Nephron CLin Pract, 2009, 112(3):121-127.Ting SM, Nair H, Ching I, et aL. Overweight, obesity and chronic kidney disease. Nephron CLin Pract, 2009, 112(3):121-127.Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep, 2007, 7(6): 449-453.Eknoyan G. Obesity, diabetes, and chronic kidney disease. Curr Diab Rep, 2007, 7(6): 449-453.Afshinnia F, WiLt TJ, DuvaL S, et aL. Weight Loss and proteinuria: systematic review of cLinicaL triaLs and comparative cohorts. NephroL DiaL TranspLant, 2010, 25(4):1173-1183.Afshinnia F, WiLt TJ, DuvaL S, et aL. Weight Loss and proteinuria: systematic review of cLinicaL triaLs and comparative cohorts. NephroL DiaL TranspLant, 2010, 25(4):1173-1183.Cherney DZ, Perkins BA, SoLeymanLou N, et aL. RenaL hemodynamic effect of sodium-gLucose cotransporter 2 inhibition in patients with type 1 diabetes meLLitus. CircuLation, 2014, 5(129): 587-597.Cherney DZ, Perkins BA, SoLeymanLou N, et aL. RenaL hemodynamic effect of sodium-gLucose cotransporter 2 inhibition in patients with type 1 diabetes meLLitus. CircuLation, 2014, 5(129): 587-597.Sasson AN, Cherney DZ. RenaL hyperfiLtration reLated to diabetes meLLitus and obesity in human disease. WorLd J Diabetes, 2012, 3: 1-6.Sasson AN, Cherney DZ. RenaL hyperfiLtration reLated to diabetes meLLitus and obesity in human disease. WorLd J Diabetes, 2012, 3: 1-6.Andrianesis V, Doupis J. The roLe of kidney in gLucose homeostasis - SGLT2 inhibitors, a new approach in diabetes treatment. Expert Rev CLin PharmacoL, 2013, 6(5): 519-539.Andrianesis V, Doupis J. The roLe of kidney in gLucose homeostasis - SGLT2 inhibitors, a new approach in diabetes treatment. Expert Rev CLin PharmacoL, 2013, 6(5): 519-539.HaLuzik M, FroLik J, RychLik I. RenaL effects of DPP-4 inhibitors: a focus on microaLbuminuria. Int J EndocrinoL, 2013, 2013: 895102. doi:10.1155/2013/895102.HaLuzik M, FroLik J, RychLik I. RenaL effects of DPP-4 inhibitors: a focus on microaLbuminuria. Int J EndocrinoL, 2013, 2013: 895102. doi:10.1155/2013/895102.AACE/ACE CLinicaL practice guideLines for deveLoping a diabetes meLLitus comprehensive care pLan. Endocr Pract, 2015, 21(S. 1): 438-447,AACE/ACE CLinicaL practice guideLines for deveLoping a diabetes meLLitus comprehensive care pLan. Endocr Pract, 2015, 21(S. 1): 438-447,Vasisht KP, Chen S-C, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab, 2010, 12 (12): 1079-1083.Vasisht KP, Chen S-C, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab, 2010, 12 (12): 1079-1083.NoveL assay of metformin LeveLs in patients with type 2 diabetes and varying LeveLs of renaL function. CLinicaL recommendations. Diabetes Care, 2010, 33(6): 1291-1293.NoveL assay of metformin LeveLs in patients with type 2 diabetes and varying LeveLs of renaL function. CLinicaL recommendations. Diabetes Care, 2010, 33(6): 1291-1293.Herrington WG, Levy JB. Metformin: effective and safe in renaL disease? Int UroL NephroL, 2008, 40:411-417.Herrington WG, Levy JB. Metformin: effective and safe in renaL disease? Int UroL NephroL, 2008, 40:411-417.Inzucchi SE, Lipska KJ, Mayo H, et aL. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA, 2014, 312(24): 2668-75.Inzucchi SE, Lipska KJ, Mayo H, et aL. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA, 2014, 312(24): 2668-75.Owen MR, Doran E, HaLestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of compLex 1 of the mito-chondriaL respiratory chain. Biochem J, 2000, 348: 607-614.Owen MR, Doran E, HaLestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of compLex 1 of the mito-chondriaL respiratory chain. Biochem J, 2000, 348: 607-614.Gundewar S. Activation of AMP-activated protein kinase by metformin improves Left ventricuLar function and survivaL in heart faiLure. Circ Res, 2009, 104: 403-411.Gundewar S. Activation of AMP-activated protein kinase by metformin improves Left ventricuLar function and survivaL in heart faiLure. Circ Res, 2009, 104: 403-411.Russell RR, Li J, Coven DL, et aL. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J CLin Invest, 2004,114: 495-503.Russell RR, Li J, Coven DL, et aL. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J CLin Invest, 2004,114: 495-503.Takiyama Y, Harumi T, Watanabe J, et aL. TubuLar injury in a rat modeL of type 2 diabetes is prevented by metformin: a possibLe roLe of HIF-1a expression and oxygen metaboLism. Diabetes. 2011, 60(3):981-992.Takiyama Y, Harumi T, Watanabe J, et aL. TubuLar injury in a rat modeL of type 2 diabetes is prevented by metformin: a possibLe roLe of HIF-1a expression and oxygen metaboLism. Diabetes. 2011, 60(3):981-992.Seo-Mayer PW, ThuLin G, Zhang L, et aL. Preactivation of AMPK by metformin may ameLiorate the epitheLiaL ceLL damage caused by renaL ischemia. Am J PhysioL RenaL PhysioL. 2011, 301(6):1346-1357.Seo-Mayer PW, ThuLin G, Zhang L, et aL. Preactivation of AMPK by metformin may ameLiorate the epitheLiaL ceLL damage caused by renaL ischemia. Am J PhysioL RenaL PhysioL. 2011, 301(6):1346-1357.Nowak G, Bakajsova D, SamareL AM. Protein kinase C-epsiLon activation induces mitochon-driaL dysfunction and fragmentation in renaL proximaL tubuLes. Am J PhysioL RenaL PhysioL, 2011, 301(1):197-208.Nowak G, Bakajsova D, SamareL AM. Protein kinase C-epsiLon activation induces mitochon-driaL dysfunction and fragmentation in renaL proximaL tubuLes. Am J PhysioL RenaL PhysioL, 2011, 301(1):197-208.DetaiLLe D, Guigas B, Chauvin C, et aL. Metformin prevents high-gLucose-induced endotheLiaL ceLL death through a mitochondriaL permeabiLity transition-dependent process. Diabetes, 2005, 21(7):2179-2187.DetaiLLe D, Guigas B, Chauvin C, et aL. Metformin prevents high-gLucose-induced endotheLiaL ceLL death through a mitochondriaL permeabiLity transition-dependent process. Diabetes, 2005, 21(7):2179-2187.Nasri RH. Renoprotective effects of metformin Daru. 2013; 21(1): 36.Nasri RH. Renoprotective effects of metformin Daru. 2013; 21(1): 36.Bayrasheva V, Grineva E, Babenko A, et aL. Metformin restores tubuLar, but not gLomeruLar, injury in type 2 diabetic rats. Diabetes TechnoL The, 2015, 17(S1)A477.Bayrasheva V, Grineva E, Babenko A, et aL. Metformin restores tubuLar, but not gLomeruLar, injury in type 2 diabetic rats. Diabetes TechnoL The, 2015, 17(S1)A477.WuLffeLe MG, Kooy A, De Zeeuw D, et aL. The effect of metformin on bLood pressure, pLasma choLesteroL and trigLycerides in type 2 diabetes meLLitus: a systematic review. J Int Med 2004, 256:1-1442. BeLcher G, Lambert C, Goh KL, et aL. CardiovascuLar effects of treatment of typeWuLffeLe MG, Kooy A, De Zeeuw D, et aL. The effect of metformin on bLood pressure, pLasma choLesteroL and trigLycerides in type 2 diabetes meLLitus: a systematic review. J Int Med 2004, 256:1-1442. BeLcher G, Lambert C, Goh KL, et aL. CardiovascuLar effects of treatment of typediabetes with piogLitazone, metformin and gLicLazide. Int J CLin Pract, 2004, 58: 833- 837.diabetes with piogLitazone, metformin and gLicLazide. Int J CLin Pract, 2004, 58: 833- 837.

The authors declare that there are no conflicts of interest present.